Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(216)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Nov 10, 2024 7:35pm
RE:Why others & not Onc ( yet)…?
Not short. Just p*ssed off.
(216)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Nov 10, 2024 7:35pm
RE:Why others & not Onc ( yet)…?
Not short. Just p*ssed off.
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(188)
•••
pelaboost
X
View Profile
View Bullboard History
Post by
pelaboost
on Nov 10, 2024 7:30pm
GOBLET
@canadafan. The fifth cohort of GOBLET was supported by PanCAN.
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 10, 2024 7:18pm
RE:RE:RE:RE:Why others & not Onc ( yet)…?
" The recently reported final BRACELET-1 study results provide clear evidence of pelareorep’s ability to improve outcomes in patients with advanced breast cancer (link to press release). Patients
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 10, 2024 7:06pm
RE:RE:RE:Why others & not Onc ( yet)…?
October 04, 2024 - Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path “Having
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 10, 2024 6:59pm
RE:RE:Why others & not Onc ( yet)…?
An adaptive Phase 2 cliniclal trial for a drug that is then granted a FDA Accelerated Approval as early as when the patient enrollment stage, becomes a confirmatory trial /.post-market approval
...more
(112)
•••
spesestsemper
X
View Profile
View Bullboard History
Comment by
spesestsemper
on Nov 10, 2024 6:33pm
RE:Why others & not Onc ( yet)…?
Your a bit misleading in your post 2024-10-04 | Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 10, 2024 6:23pm
RE:RE:“Second mouse gets the cheese “
https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=35743473
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 10, 2024 6:22pm
RE:“Second mouse gets the cheese “
Read this thread for further insight.
(931)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Nov 10, 2024 5:26pm
Why others & not Onc ( yet)…?
Dealing with facts & not conjectures, Onc has the following to offer. They have strong clinical proof over countless trials of bith efficacy & safety. Some if the recent juniors bought out, we
...more
(216)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Nov 10, 2024 12:56pm
RE:RE:RE:RE:Hi all,
CF, enjoy your posts. One thing pops out in your latest. Many junior BT's with much less have been bought out. The question is why? Is it because ONC doesn't actually have less than those
...more
(931)
•••
canadafan
X
View Profile
View Bullboard History
Comment by
canadafan
on Nov 10, 2024 12:04pm
RE:RE:RE:Hi all,
I think many would be pleased to see Onc be bought out by a Roche. They certainly know Onc/ Palareorep clinical potential. They have been working alongside , with ONC for a very long time. Again
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 09, 2024 6:07pm
RE:RE:Hi all,
That prioritization into M&A dollars could be coming from Roche's TIGIT R&D program.
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 09, 2024 6:04pm
RE:Hi all,
Perhaps it has something to do with Roche having stated in their last quarterly report that they were shifting R&D dollars into M&A activities.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden